Laurus Labs Ltd
LAURUSLABSLaurus Labs Ltd
LAURUSLABSPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
170.72 | 6.15 | 0.17% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 6.64 | 0.47% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,781.94 | 1,937.03 | 2,085.36 | 2,308.07 | 2,837.64 | 4,837.17 | 4,950.87 | 6,046.55 | 5,067.17 | 5,079.20 | ||||||||||
Raw Materials | 1,033.24 | 1,031.67 | 1,088.41 | 1,267.63 | 1,629.55 | 2,455.20 | 2,414.94 | 2,752.28 | 2,533.30 | 4,271.97 | ||||||||||
Power & Fuel Cost | 57.96 | 66.27 | 94.21 | 109.37 | 136.77 | 157.75 | 204.47 | 324.10 | 338.15 | |||||||||||
Employee Cost | 175.46 | 204.73 | 238.14 | 276.33 | 320.77 | 397.04 | 469.55 | 557.43 | 614.85 | |||||||||||
Selling & Administrative Expenses | 67.97 | 92.25 | 96.07 | 140.99 | 189.38 | 239.88 | 276.15 | 291.01 | 335.07 | |||||||||||
Operating & Other expenses | 80.75 | 102.10 | 126.03 | 141.61 | -9.30 | 12.96 | 148.03 | 523.54 | 441.96 | |||||||||||
EBITDA | 366.56 | 440.01 | 442.50 | 372.14 | 570.47 | 1,574.34 | 1,437.73 | 1,598.19 | 803.84 | 807.23 | ||||||||||
Depreciation/Amortization | 86.41 | 105.98 | 125.45 | 164.19 | 187.27 | 205.07 | 251.49 | 324.08 | 384.58 | 400.09 | ||||||||||
PBIT | 280.15 | 334.03 | 317.05 | 207.95 | 383.20 | 1,369.27 | 1,186.24 | 1,274.11 | 419.26 | 407.14 | ||||||||||
Interest & Other Items | 111.11 | 99.90 | 79.64 | 88.19 | 89.59 | 68.16 | 102.39 | 165.17 | 182.90 | 192.90 | ||||||||||
PBT | 169.04 | 234.13 | 237.41 | 119.76 | 293.61 | 1,301.11 | 1,083.85 | 1,108.94 | 236.36 | 214.24 | ||||||||||
Taxes & Other Items | 35.30 | 43.86 | 69.81 | 25.99 | 38.34 | 317.53 | 256.33 | 318.83 | 75.81 | 66.03 | ||||||||||
Net Income | 133.74 | 190.27 | 167.60 | 93.77 | 255.27 | 983.58 | 827.52 | 790.11 | 160.55 | 148.21 | ||||||||||
EPS | 0.86 | 1.81 | 3.17 | 1.77 | 4.79 | 18.36 | 15.41 | 14.69 | 2.98 | 2.75 | ||||||||||
DPS | 0.10 | 0.30 | 0.30 | 0.30 | 0.50 | 2.00 | 2.00 | 2.00 | 0.80 | 0.80 | ||||||||||
Payout ratio | 0.12 | 0.17 | 0.09 | 0.17 | 0.10 | 0.11 | 0.13 | 0.14 | 0.27 | 0.29 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Laurus Labs Ltd | 157.60 | 6.15 | 0.17% |
Sun Pharmaceutical Industries Ltd | 48.19 | 6.88 | 0.70% |
Cipla Ltd | 32.68 | 5.02 | 0.78% |
Torrent Pharmaceuticals Ltd | 68.98 | 16.66 | 0.83% |
Price Comparison
Compare LAURUSLABS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.12%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.50%
Top 5 Mutual Funds holding Laurus Labs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0405% | Percentage of the fund’s portfolio invested in the stock 0.93% | Change in the portfolio weight of the stock over the last 3 months 0.93% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 38/87 (+28) |
Mirae Asset Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7316% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months -0.38% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/87 (-10) |
Kotak Equity Arbitrage Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6526% | Percentage of the fund’s portfolio invested in the stock 0.31% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 152/181 (-2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
LAURUSLABS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.70 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateMay 8, 2024
Dividend/Share
₹0.40
Ex DateEx Date
May 8, 2024
Cash Dividend
Ex DateEx DateNov 2, 2023
Dividend/Share
₹0.40
Ex DateEx Date
Nov 2, 2023
Cash Dividend
Ex DateEx DateMay 10, 2023
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2023
Cash Dividend
Ex DateEx DateNov 3, 2022
Dividend/Share
₹0.80
Ex DateEx Date
Nov 3, 2022
Cash Dividend
Ex DateEx DateMay 10, 2022
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2022
Laurus Labs Ltd fell for a fifth straight session today. The stock is quoting at Rs 463.95, down 4.42% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Laurus Labs Ltd has gained around 6.07% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 24.45 lakh shares today, compared to the daily average of 26.51 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 465.85, down 3.9% on the day. Laurus Labs Ltd jumped 17.43% in last one year as compared to a 27.59% rally in NIFTY and a 47.81% spurt in the Nifty Pharma index.The PE of the stock is 109.21 based on TTM earnings ending June 24.Powered by Capital Market - Live
Laurus Labs announced the inauguration of its state of the art new R&D center at IKP Knowledge Park, Plot No DS15, Kolthur Shamirpet Medchal Telangana. Key highlights: - Total investment incurred for setting up the new R&D Rs 250 crore - 2,00,000 Square foot facility equipped with modern laboratories and infrastructure - R&D Center to support the CDMO business of Laurus Labs - Will provide job opportunities to over 800 peoplePowered by Capital Market - Live
The pharmaceutical company said that its API manufacturing facility located at Hyderabad has completed the United States Food and Drug Administration (USFDA) inspection without any 483 observation. The USFDA conducted the inspection from 9 September 2024 to 13 September 2024. Laurus Labs' API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing active pharmaceutical ingredients, bolstering the company's ability to deliver high-quality, innovative pharmaceutical solutions to its global customers. Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit dropped 49.7% to Rs 12.51 crore in Q1 FY24 as against Rs 24.85 crore reported in Q1 FY24. Net sales was at Rs 1,194.91 crore in Q1 FY25, up 1.1% from Rs 1,181.79 crore recorded in the same period a year ago. Shares of Laurus Labs shed 0.25% to settle at Rs 505.70 on Friday, 13 September 2024.Powered by Capital Market - Live
Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 496.5, up 4.39% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Laurus Labs Ltd has risen around 17.43% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 77.3 lakh shares today, compared to the daily average of 21.43 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 497.85, up 4.08% on the day. Laurus Labs Ltd is up 21.9% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 107.07 based on TTM earnings ending June 24.Powered by Capital Market - Live
Laurus Labs Ltd rose for a fifth straight session today. The stock is quoting at Rs 443.5, up 1.39% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.11% on the day, quoting at 24726.7. The Sensex is at 80745.92, down 0.07%. Laurus Labs Ltd has added around 0.45% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 9.31% in last one month and is currently quoting at 22374.25, up 0.85% on the day. The volume in the stock stood at 6.56 lakh shares today, compared to the daily average of 29.12 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 444.05, up 1.25% on the day. Laurus Labs Ltd is up 13.35% in last one year as compared to a 27.48% gain in NIFTY and a 47.45% gain in the Nifty Pharma index.The PE of the stock is 98.42 based on TTM earnings ending June 24.Powered by Capital Market - Live
Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 435.5, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 24574.45. The Sensex is at 80465.57, up 0.04%. Laurus Labs Ltd has slipped around 1.36% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has slipped around 7.84% in last one month and is currently quoting at 22106.5, up 0.69% on the day. The volume in the stock stood at 6.04 lakh shares today, compared to the daily average of 30.63 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 435.6, up 0.93% on the day. Laurus Labs Ltd is up 12.03% in last one year as compared to a 26.71% spurt in NIFTY and a 45.17% spurt in the Nifty Pharma index.The PE of the stock is 96.89 based on TTM earnings ending June 24.Powered by Capital Market - Live
Laurus Labs Ltd soars 2.21%, Gains for third straight session
Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient
Laurus Labs Q1 net slumps to ₹13 crore on lower revenue
Board of Laurus Labs appoints director
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 1.05% to 1.34%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.28%